Literature DB >> 1373166

Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T lymphocyte responses.

M J Newman1, J Y Wu, B H Gardner, K J Munroe, D Leombruno, J Recchia, C R Kensil, R T Coughlin.   

Abstract

The ability of a saponin adjuvant, QS-21, to induce OVA-specific, class I MHC Ag-restricted CTL was investigated using different forms of soluble OVA and OVA adsorbed onto alum as immunogens. C57BL/6 mice were immunized with soluble native or denatured OVA in formulations that contained increasing quantities of QS-21, and CTL responses were measured using EL4 and E.G7-OVA cells as targets and splenic mononuclear cells as effectors. Ag-specific CTL responses were produced but only if the QS-21 adjuvant was used. Similar responses were induced using alum-adsorbed OVA when mixed with the QS-21 adjuvant but not when used alone. The CTL were specific for an epitope present on the OVA258-276 synthetic peptide, which contains the dominant CTL epitope recognized by C57BL/6 mice. The CD8+ subpopulation of lymphocytes in immune mice was not increased in spleens but increased significantly in vitro after culture with soluble OVA. The CTL activity of splenic mononuclear cell preparations was totally destroyed by treatment with mAb specific to the CD8 Ag plus complement. The ability of the QS-21 adjuvant to induce class I MHC Ag-restricted CTL after immunization with soluble proteins is a characteristic unique to saponin adjuvants.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1373166

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  31 in total

1.  Cross-linked protein crystals for vaccine delivery.

Authors:  N St Clair; B Shenoy; L D Jacob; A L Margolin
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-17       Impact factor: 11.205

2.  Vaccine adjuvants aluminum and monophosphoryl lipid A provide distinct signals to generate protective cytotoxic memory CD8 T cells.

Authors:  Megan K L MacLeod; Amy S McKee; Alexandria David; Jieru Wang; Robert Mason; John W Kappler; Philippa Marrack
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-25       Impact factor: 11.205

Review 3.  The development and use of vaccine adjuvants.

Authors:  Robert Edelman
Journal:  Mol Biotechnol       Date:  2002-06       Impact factor: 2.695

4.  Primary CD8+ T-cell response to soluble ovalbumin is improved by chloroquine treatment in vivo.

Authors:  Bruno Garulli; Maria G Stillitano; Vincenzo Barnaba; Maria R Castrucci
Journal:  Clin Vaccine Immunol       Date:  2008-08-27

Review 5.  Melanoma vaccines. Current status and future prospects.

Authors:  P Hersey
Journal:  Drugs       Date:  1994-03       Impact factor: 9.546

Review 6.  Drug delivery issues in vaccine development.

Authors:  M F Powell
Journal:  Pharm Res       Date:  1996-12       Impact factor: 4.200

7.  Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes.

Authors:  S Sasaki; K Sumino; K Hamajima; J Fukushima; N Ishii; S Kawamoto; H Mohri; C R Kensil; K Okuda
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

8.  Antibody and cytotoxic T-cell responses to soluble hepatitis B virus (HBV) S antigen in mice: implication for the pathogenesis of HBV-induced hepatitis.

Authors:  R Schirmbeck; K Melber; T Mertens; J Reimann
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

9.  Protective immunity to Brucella ovis in BALB/c mice following recovery from primary infection or immunization with subcellular vaccines.

Authors:  M P Jiménez de Bagüés; P H Elzer; J M Blasco; C M Marín; C Gamazo; A J Winter
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

10.  Poliovirus-specific major histocompatibility complex class I-restricted cytolytic T-cell epitopes in mice localize to neutralizing antigenic regions.

Authors:  M Kutubuddin; J Simons; M Chow
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.